Shareholders meeting

Ref: BHL/STEX 31/2026-27 Date: August 29, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex Bandra (East) Mumbai – 400 001 Mumbai-400051 Scrip Code: 539872 Symbol: BAJAJHCARE Subject: Intimation regarding 33rd Annual General Meeting and dispatch of Annual Report of the Company for the financial year 2025-26 Dear Sir/Madam, Pursuant to Regulation 30 & 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that 33rd Annual General Meeting (“AGM”) of Bajaj Healthcare Limited (“the Company”) is scheduled to be held on Monday, September 21, 2026 at 3.00 p.m. (IST) through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”) only. Further, pursuant to Regulation 36(1)(b) of the Listing Regulations, the Company has dispatched letters to Shareholders whose e-mail addresses are not registered with the Company or their Depository Participants (DPs), providing the web link to access the Annual Report on the website of the Company. The schedule of events of 33rd AGM is set out below: Particulars Details Date of sending the Notice of AGM via e-mail Saturday, August 29, 2026 Day, Date & Time of AGM Monday, September 21, 2026 at 3.00 p.m. (IST) Cut-off Date for e-voting Monday, September 14, 2026 E-Voting Start Date Thursday, September 17, 2026 at 9:00 am (IST) E-Voting End Date Sunday, September 20, 2026 upto 5:00 pm (IST) Members attending the AGM who have not cast their vote by remote e-voting, shall be entitled to vote at AGM through e-voting during the AGM. The Notice of the 33rd AGM and Annual Report for the financial year 2025-26 are attached herewith and also available on the website of the Company i.e. www.bajajhealth.com Kindly take the above information on your record. Thanking you, Yours Faithfully, For and on behalf of Bajaj Healthcare Limited Monica Tanwar Company Secretary & Compliance Officer Encl: as above BAJAJ HEALTHCARE LIMITED Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604 Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com CIN No. L99999MH1993PLC072892 FROM MOLECULE TO MEDICINE BAJAJ HEALTHCARE LIMITED ANNUAL REPORT FY 2025-26 Contents Company Overview 02 Corporate snapshot 04 How we have performed across the years About the report 05 Chairman and Managing Director's message 08 Managing Director's business review This Annual Report of Bajaj 10 Chied Financial Officer's financial prespective Healthcare Limited for 12 Our Active Pharmaceutical Ingredients and Intermediates FY 2025–26 presents a business comprehensive overview of the Company’s financial and non- 14 Our Finished Dosage Formulations business financial performance, covering 16 Manufacturing excellence: From science to scale the period from 1st April 2025, to 20 The people behind the science 31st March 2026. 22 Building responsibly, operating safely 24 Corporate Social Responsibility at Bajaj Healthcare 26 Board of Directors Statutory Reports 28 Management Discussion and Analysis 39 Corporate Information 40 Director’s Report 59 Report on Corporate Governance 90 Business Responsibility and Sustainability Report Financial Statements 134 Independent Auditor’s Report 144 Balance Sheet 145 Statement of Profit and Loss 146 Statement of Cash Flows 148 Statement of Changes in Equity 149 Notes on the Financial Statements 199 Notice Forward looking statement Some information in this report may contain forward-looking statements. We have based these forward-looking statements on our current beliefs, expectations and intentions as to facts, actions and events that will or may occur in the future. Such statements are identified by forward-looking words such as “believe,” “plan,” “anticipate,” “continue,” “estimate,” “expect,” “may,” “will” or other similar words. A forward-looking statement may include a statement of the assumptions or basis underlying the forward-looking statement. We have chosen these assumptions or basis in good faith, and we believe that they are reasonable in all material respects. However, we caution you that forward-looking statements and assumed facts or bases almost always vary from actual results, and the differences between the results implied by the forward-looking Online Annual report statements and assumed facts or bases and actual results can www.bajajhealth.com be material, depending on the circumstances. FROM MOLECULE TO MEDICINE Some opportunities take years of preparation before they translate into medicines and markets. For Bajaj Healthcare, FY 2025-26 was a year of building the capabilities to move further along the pharmaceutical value chain. The Company progressed beyond its established API business, investing in specialized molecules, formulation capabilities, peptide manufacturing and regulatory preparedness. This evolution builds on capabilities developed over the decades, spanning chemistry, manufacturing, research, regulatory experience and customer relationships. The next phase will enable to move up the value chain to enter new therapeutic spaces and build capabilities ahead of demand. The journey is therefore not simply in moving from one product to another. It is in moving from molecules to medicines, accompanied by capabilities to create greater value at every stage. Bajaj Healthcare Limited Annual Report FY 2025-26 CORPORATE SNAPSHOT Bajaj Healthcare Limited exists at the point where chemistry becomes healthcare. The Company develops and manufactures API, intermediate products and formulations – all three. These address opportunities in the pharmaceutical, nutraceutical and food sector segments. These products begin as molecules in a laboratory. They progress through process development, synthesis, testing, scale- up, commercial manufacturing, quality assurance and regulatory documentation. They reach customers with the consistency, reliability and compliance expected from a dependable pharmaceutical partner. Three decades of Leadership pharmaceutical evolution foundation From one API operation to a Built on entrepreneurial vision. broader pharmaceutical platform Strengthened by experience. Bajaj Healthcare’s journey began with the The Company’s journey is rooted manufacture of APIs in 1993 and evolved in the entrepreneurial vision of into a diversified pharmaceutical platform. Mr. Sajankumar R. Bajaj and Mr. Anil C. Over three decades, the Company has Jain, who recognized India’s potential expanded its manufacturing capabilities, as a dependable global pharmaceutical product portfolio and market presence, manufacturing base. Today, this building a broader platform across the foundation is supported by an pharmaceutical value chain. experienced management team across manufacturing, research, quality, finance, procurement, marketing and business development. Company Overview Statutoty Reports Financial Statements Integrated Scale and operating presence Manufacturing capability pharmaceutical platform More of the value chain. More Built to make complexity work. Turning science into dependable possibilities. production. Bajaj Healthcare operates across As of 31st March 2026, the Company Bajaj Healthcare’s manufacturing network intermediates, APIs, finished dosage operated 20 manufacturing facilities integrates production, engineering, formulations, nutraceutical products across two states – Gujarat and quality, testing and process control. and specialized alkaloid processing, Maharashtra, offered more than 250 As of 31st March 2026, the Company enabling it to participate across multiple products and served over 575 customers possessed API and Intermediates stages of the pharmaceutical value across 60 countries. Its network capacity of 824 MT per month, and chain. Its integrated capabilities across brings together diverse chemistries, finished dosage formu [Showing first 8,000 characters — download PDF for full document]